Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus chemotherapy or ipilimumab in early stage NSCLC
NCT02998528Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02998528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998528.